Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various national committee for clinical laboratory standards susceptibility test methods-Reference-Cited by-同舟云学术

Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various national committee for clinical laboratory standards susceptibility test methods

Published:1994-05 Issue:1 Volume:19 Page:65-68
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Bale Martha J.,Jones Ronald N.,Erwin Meridith E.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference9 articles.

1. Ceftizoxime interpretive criteria for in vitro susceptibility tests with Neisseria gonorrhoeae;Barrett;J Clin Microbiol,1993

2. Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents;Barry;Diagn Microbiol Infect Dis,1989

3. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin;Fu;Antimicrob Agents Chemother,1992

4. Approved standard M7-A2: methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically;National Committee for Clinical Laboratory Standards (NCCLS),1990

5. Tentative guideline M23-T2: development of in vitro susceptibility testing criteria and quality control parameters;National Committee for Clinical Laboratory Standards (NCCLS),1992

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bacterial Infections in the Elderly Patient: Focus on Sitafloxacin;Clinical Medicine Insights: Therapeutics;2012-01

2. In vitro activity of grepafloxacin againstHaemophilus influenzae andMoraxella catarrhalis;European Journal of Clinical Microbiology & Infectious Diseases;1998-04

3. Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group;Antimicrobial Agents and Chemotherapy;1996-07

4. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628);Diagnostic Microbiology and Infectious Disease;1995-03

5. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin);Diagnostic Microbiology and Infectious Disease;1995-01